PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Announces Phosphospecific Antibodies Production - Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that results in the modification of the activity of the phosphorylated molecule by inducing small conformational changes within the molecule.1-2 - AnaSpec.com
AnaSpec Announces Phosphospecific Antibodies Production

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/08/06 - Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that results in the modification of the activity of the phosphorylated molecule by inducing small conformational changes within the molecule.1-2 - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Catalyzed by protein kinases, phosphate groups can be added via the transfer of the terminal phosphate from a phosphate donor, e.g. ATP to an amino acid residue, such as serine, threonine or tyrosine (Figure 1). The functions of phosphorylation, the most prevalent of post-translational modifications, include the alteration of the activity of a substrate, its subcellular localization, binding properties with other proteins.1-2 To better understand phosphorylation and its functional role, the generation and use of phosphospecific antibodies is crucial.

For raising antibodies against phosphopeptides there are 3 critical factors for success: (1) the stability of the phosphorylation, (2) the purity of the peptide and (3) post-development purification of the phosphospecific antibody. With documented experience in meeting all three factors, AnaSpec, EGT Group is a proven source for world-class phosphospecific antibody production.

With full manufacturing facilities located in Fremont, CA, AnaSpec (anaspec.com) is able to maintain ISO9001:2008 manufacturing processes and robust quality validation. Our peptide chemists routinely synthesize sequences containing single and multiple phosphoamino acids using technologies that are fine-tuned to produce high-yield, ultra-pure phosphopeptides. Antibodies generated are then substantiated to be phosphospecific.
AnaSpec offers both polyclonal and monoclonal antibody production services for the generation of phospho and non-phosphospecific antibodies. For polyclonal antibodies, researchers have a choice between two immunization protocols - the Speedy 28-day protocol (an example of results is shown in Figure 2) and the 70-day standard protocol. As a trusted provider to the global research community, we are experienced in fulfilling the most stringent demands for optimizing project success. As well, AnaSpec carries a wide selection of phosphospecific catalog antibodies such as the Anti-p53’s and Anti-TAU’s. Phosphospecific antibodies that are zebrafish reactive are also available.

References:
1. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Section 10.4, Covalent Modification Is a Means of Regulating Enzyme Activity.
2. Cohen, P. Proc R Soc Lond 234, 115 (1998). doi: 10.1098/rspb.1988.0040.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Announces Phosphospecific Antibodies Production

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)